Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism



Page Path
HOME > Search
4 "Min Jung Lee"
Article type
Publication year
Funded articles
Original Articles
Diabetes, Obesity and Metabolism
Prognostic Value of Triglyceride and Glucose Index for Incident Type 2 Diabetes beyond Metabolic Health and Obesity
Hwi Seung Kim, Jiwoo Lee, Yun Kyung Cho, Eun Hee Kim, Min Jung Lee, Hong-Kyu Kim, Joong-Yeol Park, Woo Je Lee, Chang Hee Jung
Endocrinol Metab. 2021;36(5):1042-1054.   Published online October 21, 2021
  • 3,827 View
  • 120 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   CrossRef-TDMCrossref - TDM
Metabolically healthy obese (MHO) phenotype is metabolically heterogeneous in terms of type 2 diabetes (T2D). Previously, the triglyceride and glucose (TyG) index has been considered for identifying metabolic health and future risk of T2D. This study aimed to evaluate the risk of incident T2D according to obesity status and metabolic health, categorized by four different criteria and the TyG index.
The study included 39,418 Koreans without T2D at baseline. The risk of T2D was evaluated based on four different definitions of metabolic health and obesity status and according to the baseline TyG index within each metabolic health and obesity group.
During the median follow-up at 38.1 months, 726 individuals developed T2D. Compared with the metabolically healthy non-obese (MHNO) group with low TyG index, the MHO group with high TyG index showed increased risk of T2D in all four definitions of metabolic health with multivariate-adjusted hazard ratios of 2.57 (95% confidence interval [CI], 1.76 to 3.75), 3.72 (95% CI, 2.15 to 6.43), 4.13 (95% CI, 2.67 to 6.38), and 3.05 (95% CI, 2.24 to 4.15), when defined by Adult Treatment Panel III, Wildman, Karelis, and homeostasis model assessment (HOMA) criteria, respectively.
MHO subjects with high TyG index were at an increased risk of developing T2D compared with MHNO subjects, regardless of the definition of metabolic health. TyG index may serve as an additional factor for predicting the individual risk of incident T2D in MHO subjects.
Clinical Study
Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
Jaehyun Bae, Min Jung Lee, Eun Yeong Choe, Chang Hee Jung, Hye Jin Wang, Myoung Soo Kim, Yu Seun Kim, Joong-Yeol Park, Eun Seok Kang
Endocrinol Metab. 2016;31(1):161-167.   Published online March 16, 2016
  • 4,747 View
  • 56 Download
  • 18 Citations
AbstractAbstract PDFPubReader   CrossRef-TDMCrossref - TDM

The use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been fully investigated. We compared the glucose-lowering efficacies of DPP 4 inhibitors and evaluate their effects on the blood levels of cyclosporine in renal transplant recipients with diabetes.


Sixty-five renal allograft recipients who received treatment with DPP-4 inhibitors (vildagliptin, sitagliptin, or linagliptin) following kidney transplant were enrolled. The glucose-lowering efficacies of the DPP-4 inhibitors were compared according to the changes in the hemoglobin A1c (HbA1c) levels after 3 months of treatment. Changes in the trough levels of the cyclosporine were also assessed 2 months after treatment with each DPP-4 inhibitor.


HbA1c significantly decreased in the linagliptin group in comparison with other DPP-4 inhibitors (vildagliptin –0.38%±1.03%, sitagliptin –0.53%±0.95%, and linagliptin –1.40±1.34; P=0.016). Cyclosporine trough levels were significantly increased in the sitagliptin group compared with vildagliptin group (30.62±81.70 ng/mL vs. –24.22±53.54 ng/mL, P=0.036). Cyclosporine trough levels were minimally changed in patients with linagliptin.


Linagliptin demonstrates superior glucose-lowering efficacy and minimal effect on cyclosporine trough levels in comparison with other DPP-4 inhibitors in kidney transplant patients with diabetes.


Citations to this article as recorded by  
  • Diabetic Kidney Disease in Post-Transplant Diabetes Mellitus: Causes, Treatment and Outcomes
    Lee-Moay Lim, Jer-Ming Chang, Hung-Tien Kuo
    Biomedicines.2023; 11(2): 470.     CrossRef
  • Sweet and simple as syrup: A review and guidance for use of novel antihyperglycemic agents for post‐transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation
    S. Elise Lawrence, Mary Moss Chandran, Jeong M. Park, Helen Sweiss, Thomas Jensen, Palak Choksi, Barrett Crowther
    Clinical Transplantation.2023;[Epub]     CrossRef
  • Interventions Against Posttransplantation Diabetes: A Scientific Rationale for Treatment Hierarchy Based on Literature Review
    Adnan Sharif
    Transplantation.2022; 106(12): 2301.     CrossRef
  • Dipeptidyl Peptidase-4 Inhibitor Decreases Allograft Vasculopathy Via Regulating the Functions of Endothelial Progenitor Cells in Normoglycemic Rats
    Feng-Yen Lin, Chun-Min Shih, Chun-Yao Huang, Yi-Tin Tsai, Shih-Hurng Loh, Chi-Yuan Li, Cheng-Yen Lin, Yi-Wen Lin, Chien-Sung Tsai
    Cardiovascular Drugs and Therapy.2021; 35(6): 1111.     CrossRef
  • Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients
    Sonya Anderson, Laura Cotiguala, Sarah Tischer, Jeong Mi Park, Katie McMurry
    Annals of Pharmacotherapy.2021; 55(4): 496.     CrossRef
  • Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis
    Dora Oikonomaki, Evangelia Dounousi, Anila Duni, Stefanos Roumeliotis, Vassilios Liakopoulos
    Diabetes Research and Clinical Practice.2021; 172: 108604.     CrossRef
  • CD161a-positive natural killer (NK) cells and α-smooth muscle actin-positive myofibroblasts were upregulated by extrarenal DPP4 in a rat model of acute renal rejection
    Franziska Schmid, Christina Mayer, Maike Büttner-Herold, Stephan von Hörsten, Kerstin Amann, Christoph Daniel
    Diabetes Research and Clinical Practice.2021; 173: 108691.     CrossRef
  • Current Pharmacological Intervention and Medical Management for Diabetic Kidney Transplant Recipients
    Theerawut Klangjareonchai, Natsuki Eguchi, Ekamol Tantisattamo, Antoney J. Ferrey, Uttam Reddy, Donald C. Dafoe, Hirohito Ichii
    Pharmaceutics.2021; 13(3): 413.     CrossRef
  • Recent advances in new-onset diabetes mellitus after kidney transplantation
    Tess Montada-Atin, G V Ramesh Prasad
    World Journal of Diabetes.2021; 12(5): 541.     CrossRef
  • Safety and Efficacy of Long-Term Administration of Dipeptidyl peptidase IV Inhibitors in Patients With New Onset Diabetes After Kidney Transplant
    Adamantia Mpratsiakou, Marios Papasotiriou, Theodoros Ntrinias, Konstantinos Tsiotsios, Evangelos Papachristou, Dimitrios S. Goumenos
    Experimental and Clinical Transplantation.2021; 19(5): 411.     CrossRef
  • Medical management of metabolic and cardiovascular complications after liver transplantation
    Chiara Becchetti, Melisa Dirchwolf, Vanessa Banz, Jean-François Dufour
    World Journal of Gastroenterology.2020; 26(18): 2138.     CrossRef
  • Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Kidney Transplant Recipients with Post-transplant Diabetes Mellitus (PTDM)- a Systematic Review and Meta-Analysis
    Tarek Samy Abdelaziz, Ahmed Yamany Ali, Moataz Fatthy
    Current Diabetes Reviews.2020; 16(6): 580.     CrossRef
  • NAFLD and liver transplantation: Disease burden, current management and future challenges
    Patrizia Burra, Chiara Becchetti, Giacomo Germani
    JHEP Reports.2020; 2(6): 100192.     CrossRef
  • Linagliptin plus insulin for hyperglycemia immediately after renal transplantation: A comparative study
    Rodolfo Guardado-Mendoza, David Cázares-Sánchez, María Lola Evia-Viscarra, Lilia M. Jiménez-Ceja, Edgar G. Durán-Pérez, Alberto Aguilar-García
    Diabetes Research and Clinical Practice.2019; 156: 107864.     CrossRef
  • Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment
    Maria J. Peláez-Jaramillo, Allison A. Cárdenas-Mojica, Paula V. Gaete, Carlos O. Mendivil
    Diabetes Therapy.2018; 9(2): 521.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • Drug–drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus
    Thomas Vanhove, Quinten Remijsen, Dirk Kuypers, Pieter Gillard
    Transplantation Reviews.2017; 31(2): 69.     CrossRef
  • Risk assessment and management of post-transplant diabetes mellitus
    Eugene Han, Myoung Soo Kim, Yu Seun Kim, Eun Seok Kang
    Metabolism.2016; 65(10): 1559.     CrossRef
Case Reports
Adrenal gland
Multiple Myeloma in a Patient with Acromegaly
Yu Mi Kang, Jong Han Choi, Min Jung Lee, Ari Ahn, Chan-Jeoung Park, Kiju Chang, Seyoung Seo, Sun In Hong, Min-Seon Kim
Endocrinol Metab. 2015;30(1):110-115.   Published online March 27, 2015
  • 4,290 View
  • 32 Download
  • 1 Citations
AbstractAbstract PDFPubReader   CrossRef-TDMCrossref - TDM

Acromegaly is a slowly progressing condition resulting from excess growth hormone (GH), generally caused by a GH-secreting pituitary adenoma. Cancer is the third most common cause of mortality in patients with acromegaly, and insulin-like growth factor 1 (IGF-1) is known to influence tumor formation by increasing cell proliferation and inhibiting apoptosis. Multiple myeloma (MM) is a plasma cell neoplasm, and previous studies have suggested the possible role of IGF-1 in its development of MM. However, no cases of acromegaly accompanied with MM have been reported in Asia to date. We here report the case of a 58-year-old woman with acromegaly accompanied with MM who presented with longstanding acromegalic manifestations resulting from a GH-secreting pituitary adenoma and also exhibited anemia, a reversed albumin/globulin ratio, and plasmacytosis on bone marrow examination. Because IGF-1 has been suggested to play an important role in the development and progression of MM, the patient promptly underwent surgical removal of the pituitary adenoma via a transsphenoidal approach. Since there is currently no consensus on therapeutic guidelines and suggested prognosis for MM with acromegaly, long-term follow-up of such cases is needed.


Citations to this article as recorded by  
  • Co-Occurrence of Acromegaly and Hematological Disorders: A Myth or Common Pathogenic Mechanism
    Prakamya Gupta, Pinaki Dutta
    Integrative Medicine International.2017; 4(1-2): 94.     CrossRef
A Case of Malignant Pheochromocytoma Presenting as Inverted Takotsubo-Like Cardiomyopathy.
Jung Eun Jang, Hyuk Hee Kwon, Min Jung Lee, Chang Hee Jung, Sung Jin Bae, Hong Kyu Kim, Woo Je Lee
Endocrinol Metab. 2012;27(1):98-104.   Published online March 1, 2012
  • 1,648 View
  • 20 Download
AbstractAbstract PDF
Takotsubo cardiomyopathy or stress induced cardiomyopathy is characterized by acute transient left ventricular apical ballooning without significant coronary artery disease. The pathophysiology of Takotsubo cardiomyopathy remains unclear, but it has been suggested that the stress related neurohumoral factors, especially catecholamines, play an important role. Recently, several reports have described an inverted Takotsubo cardiomyopathy, which is characterized by the dysfunction of the basal and mid-ventricular segments sparing the apex of the heart. In this report, we present a case of a 50-year-old female with a transient left ventricular dysfunction in an inverted Takotsubo pattern, that later was diagnosed as a malignant pheochromocytoma.

Endocrinol Metab : Endocrinology and Metabolism